Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ministry of Health, Labour and Welfare, Abridged Life Table for Japan 2006
Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403
Berlin, 2002, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297, J Clin Oncol, 20, 3270, 10.1200/JCO.2002.11.149
Louvet, 2005, Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial, J Clin Oncol, 23, 3509, 10.1200/JCO.2005.06.023
Oettle, 2005, A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer, Ann Oncol, 16, 1639, 10.1093/annonc/mdi309
Van Cutsem, 2004, Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer, J Clin Oncol, 22, 1430, 10.1200/JCO.2004.10.112
Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525
Plate, 2005, Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas, Cancer Immunol Immunother, 54, 915, 10.1007/s00262-004-0638-1
Choi, 1989, Interaction of Staphylococcus aureus toxin ‘superantigens’ with human T cells, Proc Natl Acad Sci USA, 86, 8941, 10.1073/pnas.86.22.8941
Labrecque, 1993, Human T cells respond to mouse mammary tumor virus-encoded superantigen: V beta restriction and conserved evolutionary features, J Exp Med, 177, 1735, 10.1084/jem.177.6.1735
Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat Med, 10, 909, 10.1038/nm1100
Hoos, 2007, A clinical development paradigm for cancer vaccines and related biologics, J Immunother, 30, 1, 10.1097/01.cji.0000211341.88835.ae
Menard, 2008, Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity, Cancer Immunol Immunother, 57, 1579, 10.1007/s00262-008-0505-6
Zitvogel, 2008, Immunological aspects of cancer chemotherapy, Nat Rev Immunol, 8, 59, 10.1038/nri2216
Ghiringhelli, 2007, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, 56, 641, 10.1007/s00262-006-0225-8
Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med, 13, 1050, 10.1038/nm1622
Lacour, 2001, Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis, Cancer Res, 61, 1645
Micheau, 1997, Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity, J Natl Cancer Inst, 89, 783, 10.1093/jnci/89.11.783
Zisman, 2001, Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis, J Immunother, 24, 459, 10.1097/00002371-200111000-00003
Correale, 2005, Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro, J Immunol, 175, 820, 10.4049/jimmunol.175.2.820
Suzuki, 2005, Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clin Cancer Res, 11, 6713, 10.1158/1078-0432.CCR-05-0883
Nowak, 2002, Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy, Cancer Res, 62, 2353
Nowak, 2003, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors, Cancer Res, 63, 4490
Bauer, 2007, Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model, Gut, 56, 1275, 10.1136/gut.2006.108621
Correale, 2005, Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients, J Clin Oncol, 23, 8950, 10.1200/JCO.2005.12.147
Bang, 2006, Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer, Pancreas, 32, 29, 10.1097/01.mpa.0000191651.32420.41
Almand, 2000, Clinical significance of defective dendritic cell differentiation in cancer, Clin Cancer Res, 6, 1755
Oyama, 1998, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells, J Immunol, 160, 1224, 10.4049/jimmunol.160.3.1224
Gabrilovich, 1996, Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 2, 1096, 10.1038/nm1096-1096
Morita, 2006, Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation, Int J Cancer, 119, 1360, 10.1002/ijc.21960
Inoue, 1994, WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia, Blood, 84, 3071, 10.1182/blood.V84.9.3071.3071
Loeb, 2001, Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation, Cancer Res, 61, 921
Oji, 1999, Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth, Jpn J Cancer Res, 90, 194, 10.1111/j.1349-7006.1999.tb00733.x
Morita, 2006, A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data, Jpn J Clin Oncol, 36, 231, 10.1093/jjco/hyl005
Oka, 2004, Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression, Proc Natl Acad Sci USA, 101, 13885, 10.1073/pnas.0405884101